Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Ovid Therapeutics (OVID) Other Gross PP&E Adjustments (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Other Gross PP&E Adjustments readings, the most recent being -$11.0 million for Q1 2026.

  • Quarterly Other Gross PP&E Adjustments rose 9.92% to -$11.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$11.0 million through Mar 2026, up 9.92% year-over-year, with the annual reading at -$16.4 million for FY2025, 9.05% up from the prior year.
  • Other Gross PP&E Adjustments hit -$11.0 million in Q1 2026 for Ovid Therapeutics, up from -$16.4 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at -$10.4 million in Q3 2025 and bottomed at -$19.7 million in Q4 2023.
  • Average Other Gross PP&E Adjustments over 5 years is -$14.1 million, with a median of -$13.8 million recorded in 2023.
  • The largest annual shift saw Other Gross PP&E Adjustments plummeted 1187.73% in 2022 before it grew 18.85% in 2023.
  • Ovid Therapeutics' Other Gross PP&E Adjustments stood at -$19.0 million in 2022, then dropped by 3.57% to -$19.7 million in 2023, then increased by 8.4% to -$18.0 million in 2024, then grew by 9.05% to -$16.4 million in 2025, then skyrocketed by 32.95% to -$11.0 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Other Gross PP&E Adjustments are -$11.0 million (Q1 2026), -$16.4 million (Q4 2025), and -$10.4 million (Q3 2025).